Brief: Cannabinoids for Medicinal Use
In February 2014, the Medical Innovation Bill, which proposes legalising the use of medical marijuana, was introduced in the South African parliament. According to the brief’s authors, it is probably that further legislation on the use of medical marijuana will come before parliament in the future. Thus, the four-page brief aims to synthesize current evidence on medical marijuana to inform debate and policy-making.
The brief begins by defining marijuana or cannabis and outlining its active ingredients, estimates of its use in South Africa and its legal status.
It then presents a summary of the systematic review including inclusion criteria, methods and results in regards to particular conditions including cancer and chemotherapy, HIV as well as multiple sclerosis.
The review concludes that there is evidence of moderate quality to support the use of cannabinoids for the treatment of chronic pain and to reduce
spasticity in multiple sclerosis patients but the clinical significance of this is unclear.
The review also notes that low quality evidence suggests cannabinoids are associated with improvements in nausea and vomiting due to chemotherapy, and weight gain in HIV infection. It notes that there are safety concerns as reflected in the greater number of short-term adverse events reported in those using cannabinoids and the lack of long-term data from rigorous studies.
Finally it cautions that approval of any medication goes beyond effectiveness and safety. Policy-makers will be required to consider supply, regulation, route of administration, and cost-effectiveness, as well as the values and preferences of the broader population.
Download the brief: Cannabinoids for Medicinal Use
Read the original JAMA article
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Brief: Cannabinoids for Medicinal Use
by healthe, Health-e News
January 11, 2016